GH Key Statistics, Chart & Performance
The current stock price of GH is 102.14 USD. In the past month the price decreased by -1.67%. In the past year, price increased by 202.55%.
GH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 11.59 | 100.74B | ||
| CI | THE CIGNA GROUP | 9.69 | 73.52B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 123.74 | 22.76B | ||
| LH | LABCORP HOLDINGS INC | 15.86 | 20.80B | ||
| DGX | QUEST DIAGNOSTICS INC | 17.78 | 19.30B | ||
| DVA | DAVITA INC | 12.31 | 8.02B | ||
| HIMS | HIMS & HERS HEALTH INC | 60.13 | 7.39B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 36.72 | 6.75B | ||
| CHE | CHEMED CORP | 19.45 | 6.06B | ||
| RDNT | RADNET INC | 187.76 | 5.50B | ||
| OPCH | OPTION CARE HEALTH INC | 21.38 | 5.06B | ||
| WGS | GENEDX HOLDINGS CORP | 69.18 | 3.76B |
Related stock screener links
About GH
Company Profile
Guardant Health, Inc. is a precision oncology company, which engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. The company is headquartered in Palo Alto, California and currently employs 1,999 full-time employees. The company went IPO on 2018-10-04. The company provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. The company offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
Company Info
GUARDANT HEALTH INC
3100 Hanover Street
Palo Alto CALIFORNIA 94063 US
CEO: Helmy Eltoukhy
Employees: 1999
Phone: 18556988887
GUARDANT HEALTH INC / GH FAQ
What does GUARDANT HEALTH INC do?
Guardant Health, Inc. is a precision oncology company, which engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. The company is headquartered in Palo Alto, California and currently employs 1,999 full-time employees. The company went IPO on 2018-10-04. The company provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. The company offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
What is the current price of GH stock?
The current stock price of GH is 102.14 USD. The price increased by 1.53% in the last trading session.
Does GH stock pay dividends?
GH does not pay a dividend.
What is the ChartMill rating of GUARDANT HEALTH INC stock?
GH has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about GUARDANT HEALTH INC (GH) stock?
33 analysts have analysed GH and the average price target is 109.15 USD. This implies a price increase of 6.86% is expected in the next year compared to the current price of 102.14.
What is the employee count for GH stock?
GUARDANT HEALTH INC (GH) currently has 1999 employees.
GH Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to GH. When comparing the yearly performance of all stocks, GH is one of the better performing stocks in the market, outperforming 98.72% of all stocks.
GH Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GH. Both the profitability and financial health of GH have multiple concerns.
GH Financial Highlights
Over the last trailing twelve months GH reported a non-GAAP Earnings per Share(EPS) of -3.26. The EPS increased by 1.21% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.23% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
GH Forecast & Estimates
33 analysts have analysed GH and the average price target is 109.15 USD. This implies a price increase of 6.86% is expected in the next year compared to the current price of 102.14.
For the next year, analysts expect an EPS growth of 33.8% and a revenue growth 32.84% for GH